Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

Poison-control centers are seeing a steady increase in calls related to weight-loss drugs, and the FDA shared a report ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...